- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00103896
Connect to Protect Partnerships for Youth Prevention Interventions: Phase II
Connect to Protect (C2P) Partnerships for Youth Prevention Interventions: Phase II
This is Phase II of a three stage project whose overall goals are to develop viable community-based HIV prevention interventions and to form and maintain the necessary community collaborations to support such Adolescent Trials Network (ATN) research activities.
This phase will describe specific locations within high-risk areas where youth, ages 12-24, spend time. HIV risk behaviors, social networking patterns and HIV prevalence among youth at these venues will be assessed by administering anonymous computerized interviews to eligible and willing youth. This information will be shared with community partners during scheduled working group meetings.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
This is Phase II of a three stage project whose overall goals are to develop viable community-based HIV prevention interventions and to form and maintain the necessary community collaborations to support such ATN research activities.
During this phase, each ATN site will gather additional information within high-risk areas and solicit community partner input to ultimately pinpoint the specific locations where at-risk youths, ages 12-24, may be recruited for interventions. This will be done by the following methods:
Venues will be identified by HIV+ youth at the ATN site by participation in an anonymous computerized interview. Site staff will then perform brief venue interviews (BVIs) at selected venues to assess the potential yield of youths 12-24 years old. Community partners will also provide the site staff with information on known high-risk venues. High-risk venues will further be identified by the results of anonymous computerized interviews and HIV assays obtained from eligible and willing youth participants at the venues. The interviews will gather information on HIV risk behaviors, social networking patterns and HIV prevalence among youths at these venues. This information will be shared with community partners during scheduled working group meetings.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90054
- Childrens Hospital of Los Angeles
-
San Diego, California, Estados Unidos, 92103
- UCSD Mother, Child & Adolescent HIV Program
-
San Francisco, California, Estados Unidos, 94143
- Univ of Califormia at San Francisco
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20010
- Children's Hospital National Medical Center
-
-
Florida
-
Ft. Lauderdale, Florida, Estados Unidos, 33301
- Children's Diag. and Treatment Center
-
Miami, Florida, Estados Unidos, 33101
- University of Miami
-
Tampa, Florida, Estados Unidos, 33606
- USF Peds Div. of Infectious Disease
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Stroger Hospital of Cook County
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70112
- Tulane Medical Center
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- University of Maryland
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Childrens' Hospital of Boston
-
-
New York
-
Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center, Adolescent AIDS Program
-
New York, New York, Estados Unidos, 10128
- Mount Sinai Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Children's Hopsital of Philadelphia
-
-
-
-
-
San Juan, Puerto Rico, 00936
- University Pediatric Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
Index Subjects:
- Documented HIV-infection
- Acquisition of HIV after age 9 years
- Verbal confirmation of 12-24 years of age
- Verbal report of having engaged in sexual activity (vaginal, anal and/or oral sex) within the past 12 months
- Ability to understand and willingness to provide informed consent/assent
BVI subjects:
- Youths who appear to be 12-24 years old
HIV Serosurvey subjects at the venues:
- Verbal confirmation of 12-24 years of age
- Verbal report of having engaged in sexual activity (vaginal, anal and/or oral sex) within the past 12 months
- Ability to understand and willingness to provide informed consent/assent
Exclusion Criteria:
- Visibly distraught and/or emotionally unstable (i.e. depressive mood, exhibiting manic, suicidal or violent behavior, etc.)
- Visibly intoxicated or under the influence of psychoactive agents
- Clinically presents as acutely ill
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
HIV Infected Youth in Treatment/Care
HIV infected youth in treatment/care will be interviewed using Audio Computer-Assisted Self-Administered Interview ACASI technology to reveal possible venues where youth at high risk for acquiring the disease may be found (N = 20-30 individuals per ATN site).
|
|
BVI Individuals
Additional data will be gathered on potential recruitment venues by administering a brief venue interview (BVI) to individuals who appear to be between 12 and 24 years old (N = unlimited individuals during 3-5 assessment periods per venue each lasting 5 hours).
|
|
HIV Serosurvey Individuals
HIV Serosurvey Individuals Anonymous structured interview using ACASI technology and an anonymous HIV antibody assay will be administered to 20-30 young women at 2-3 targeted locations and 20-30 young men at 2-3 targeted locations whose HIV status is unknown (N = 160-360 individuals per ATN site)..
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Ascertain specific community venues where at-risk youth can be recruited for interventions within the high-risk areas identified in the first Phase of the study
Periodo de tiempo: One time assessment at 10 months
|
The outcome measure will be assessed using results from: (a) Phase I mapping; (b) Phase II interviews with HIV-infected youth; and (c) Phase II Brief Venue Interviews (BVIs).
Input from community partners and ethnographic procedures will add critical information.
|
One time assessment at 10 months
|
|
Describe HIV risk behaviors of adolescents and young adults recruited from targeted venues
Periodo de tiempo: One time assessment at 10 months
|
The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown.
|
One time assessment at 10 months
|
|
Describe social networks of adolescents and young adults recruited from targeted venues
Periodo de tiempo: One time assessment at 10 months
|
The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown.
|
One time assessment at 10 months
|
|
Describe HIV seroprevalence of adolescents and young adults recruited from targeted venues
Periodo de tiempo: One time assessment at 10 months
|
The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown.
|
One time assessment at 10 months
|
|
Assess the characteristics of the community-researcher partnerships
Periodo de tiempo: One time assessment at 10 months
|
The outcome measure will be assessed by conducting interviews with C2P staff and their community partners.
Questionnaires will be completed by both parties and detailed documentation kept.
|
One time assessment at 10 months
|
|
Assess quality of the community-researcher partnerships
Periodo de tiempo: One time assessment at 10 months
|
The outcome measure will be assessed by conducting interviews with C2P staff and their community partners.
Questionnaires will be completed by both parties and detailed documentation kept.
|
One time assessment at 10 months
|
|
Assess outcomes of the community-researcher partnerships
Periodo de tiempo: One time assessment at 10 months
|
The outcome measure will be assessed by conducting interviews with C2P staff and their community partners.
Questionnaires will be completed by both parties and detailed documentation kept.
|
One time assessment at 10 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Donna Futterman, MD, Montefiore Medical Center
- Investigador principal: Sue Ellen Abdalian, MD, Tulane Medical Center
- Silla de estudio: Jonathan Ellen, MD, Johns Hopkins Medical Center
- Investigador principal: Ligia Peralta, MD, Division of Adolescent & Young Adult Medicine University of MD, Medical School
- Investigador principal: Marvin Belzer, MD, Childrens Hosp of Los Angeles, Division of Adolescent Medicine
- Investigador principal: Bret Rudy, MD, Children's Hospital of Philadelphia
- Investigador principal: Larry D'Angelo, MD, Children's National Research Institute
- Investigador principal: Cathryn Samples, MD, Boston Children's Hospital
- Investigador principal: Lisa Henry-Reid, MD, John H. Stroger Jr. Hospital and the CORE Center
- Investigador principal: Ana Puga, MD, Children's Diag. and Treatment Ctr of Ft. Lauderdale, FL
- Investigador principal: Lawrence Friedman, MD, University of Miami, School of Medicine, Div of Adolescent Medicine
- Investigador principal: Patricia Emmanuel, MD, University of South Florida, Peds Div of Infectious Disease
- Investigador principal: Linda Levin, MD, Mount Sinai Adolescent Health Center
- Investigador principal: Irma Febo, MD, University of Puerto Rico Medical Sciences Campus
- Investigador principal: Stephen A Spector, MD, UCSD Mother, Child, & Adolescent HIV Program
- Investigador principal: Rolando M Viani, MD, UCSD Mother, Child, & Adolescent HIV Program
- Investigador principal: Barbara Moscicki, MD, UCSF, Division of Adoles. Med
- Investigador principal: Coco Auerswald, MD, UCSF, Division of Adoles. Med
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
Otros números de identificación del estudio
- ATN 016b
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infección por VIH
-
Icahn School of Medicine at Mount SinaiClearPoint NeuroReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán